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I. Introduction
Since the first implementation of electronic medical record 
systems to real world applications, it has been suggested that 
a digitalized drug utilization review (DUR) at the time of 
drug prescription or dispensing would be an effective way to 
reduce errors in medication utilization [1-4].
  In the establishment of a DUR system, the most difficult 
step is digitalizing the text based information on the dos-
age range check module (DRCM) for each indication. It is 
also very important that the completed database is based on 
sources that professionals in the field (including physicians 
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Objectives: This report describes the development process of a drug dosing database for ethical drugs approved by the Korea 
Food & Drug Administration (KFDA). The goal of this study was to develop a computerized system that supports physicians’ 
prescribing decisions, particularly in regards to medication dosing. Methods: The advisory committee, comprised of doctors, 
pharmacists, and nurses from the Seoul National University Bundang Hospital, pharmacists familiar with drug databases, 
KFDA officials, and software developers from the BIT Computer Co. Ltd. analyzed approved KFDA drug dosing information, 
defined the fields and properties of the information structure, and designed a management program used to enter dosing in-
formation. The management program was developed using a web based system that allows multiple researchers to input drug 
dosing information in an organized manner. The whole process was improved by adding additional input fields and eliminat-
ing the unnecessary existing fields used when the dosing information was entered, resulting in an improved field structure. 
Results: A total of 16,994 drugs sold in the Korean market in July 2009, excluding the exclusion criteria (e.g., radioactivity 
drugs, X-ray contrast medium), usage and dosing information were made into a database. Conclusions: The drug dosing 
database was successfully developed and the dosing information for new drugs can be continually maintained through the 
management mode. This database will be used to develop the drug utilization review standards and to provide appropriate 
dosing information.
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and pharmacists) are able to trust. While several interna-
tional and domestic institutions have developed their own 
dosage databases and employed them in daily practices, 
there are considerable variations between the dosage guide-
lines that they provide. Of course, there are a number of dos-
age databases that have roots in a national standard based 
on government official resources, such as market approval 
information. Although most of these information sources 
(e.g., MICROMEDEX) are internationally available, access to 
their content is inevitably limited to a considerable degree. 
Hence, there has been an urgent demand for a national data-
base that can provide trustworthy drug dose information to 
professionals.
  In this work, therefore, the authors aim to develop a DRCM 
on which a dosage database for locally marketed ethical 
pharmaceuticals can be built based on the approved infor-
mation on indications and predefined age category dosages. 
By doing so, the foundations for establishing a standardized 
DUR system at a national level can be developed, and better, 
safer, drug therapy will be available to the general public.
  The system used in this study is unique in terms that it 
provides the dosage information for each indication defined 
in the original Korea Food & Drug Administration (KFDA) 
label. The dosage information in the labels were separated 
into three parts; dosage value (e.g., 30), unit (e.g., mg), and 
a number tag for each indication to facilitate the direct 
comparison with prescriptions written by doctors. Further-
more, instead of managing this data in generic commercial 
software (e.g., Microsoft EXCEL), a standalone database was 
developed for the efficient handling of the data in terms of 
input, management, and regeneration of information. In 
particular, the database was designed to decipher the subtle 
differences in data input that may occur for different people 
and standardize them (e.g., automatically reading the input 
100MG as 100 mg; understanding 100IU as 100 I.U.). With-
out this function, when large amounts of data are accumu-
lated, reprocessing and/or re-purification of the information 
would be inevitable. Therefore, the system presented in this 
study is likely to eliminate/minimize problems associated 
with the inefficiency.
II. Case Description
1. Advisory Committee
An advisory committee comprised of doctors, pharmacists 
and nurses from Seoul National University Bundang Hos-
pital was formed to oversee and advise the construction of 
the DUR database. The committee also included pharma-
cists familiar with drug database construction/analysis/and 
planning, the KFDA officials that are in charge of pharmacy 
affairs, and software developers from BIT Computer Co. 
Ltd. (i.e., one for Javascript and another for database con-
struction). Monthly meetings were regularly held for com-
munication, discussion and consultation on the purpose and 
contents/scope of the software.
2. Analysis of the KFDA Labels
Currently, the nomenclature and unit information are not 
fully standardized in KFDA labels. Therefore, the dosage/
usage information in these labels had to be processed and 
analyzed before writing the data into the database. This pro-
cedure decided what items would be included in the data-
base and what information considering that item would be 
introduced or left out, allowing the new database to maintain 
a consistent structure. Whenever inconsistencies were found 
in the labels, especially in usage or dosage, an advisory com-
mittee meeting was called for discussion and consultation.
3. Standardization of Dosage Process
To provide a standard working environment, the following 
process standards were implemented to enhance the reliability 
of the database while securing the convenience of workers.
1) Processing detailed information
Usage/dosage information was conceptually structured and 
processed so that information could be easily separated into 
discrete parts. The advantage here is that inconsistencies in 
dosage information can be quickly identified by the manager.
2) Separation of numerical and unit information
Since typographical errors may affect the quality of the da-
tabase if information is processed in a raw text format, the 
separation of data into number and unit fields is necessary. 
In particular, subtle differences that may occur when input-
ting units, which are mainly created by the diversity of the 
people using the program, may also affect the quality of the 
database. Therefore, only pre-registered units were allowed 
to be used in the processing of units.
3) Unit conversion
During database construction, each drug item had to have 
a complete field of information filled out. This means that 
for every item, information on its contents (e.g., major in-
gredients in the drug products), available forms of dosage 
(e.g., powder, solution and tablet), and precise dosages in 
appropriate units for each form of dosage (e.g., mg or mL) 
was processed, allowing every possible dosage unit in the 
prescription to be inter-convertible in a timely fashion. 269 Vol.	17		•		No.	4		•		December	2011 www.e-hir.org
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4) Consideration of salts
For certain drugs, the drug product contains a given salt 
form of the drug. For example, 12.79 mg of amlodipine 
mesylate monohydrate would make a 10 mg tablet of pure 
amlodipine. For the database introduced in this study, a field 
for total dosage (i.e., salt-included content) was provided for 
the easy conversion of the actual dosage of the drug (i.e., free 
acid or base).
5) Additional units for combination drugs (i.e., 2 or more 
major ingredients in the product)
If possible, the dosage information of combination drugs 
was further processed for easy conversion and flexible use. 
For example, conventional Sinotrim syrup contains 8 mg/
mL of trimethoprim and 40 mg/mL of sulfamethoxazole (i.e., 
unprocessed data). However, the dosage for the product was 
converted to 2.5 mL of Sinotrim syrup per kg body weight, 
considering the fact that the dosages for trimethoprim and 
sulfamethoxazole were 20 mg/kg and 100 mg/kg, respec-
tively.
6) Administration volume
Since some drugs, such as parenterals and ophthalmic drops, 
have a solution form (or dissolved immediately before use), 
the total volume of injection (or application) determines the 
overall concentration of the formulation. Therefore, detailed 
information on the volume of administration was provided 
in the database used in this study.
4. Design of Web-based Data Management Programs
Since information is processed by pharmacists throughout 
the hospital, it is very convenient and time saving if their in-
puts are gathered in a web environment. In addition, under 
these circumstances, managers in the project can oversee 
progress and statistically analyze the data from remote loca-
tions. This type of work environment enabled pharmacists to 
accomplish their objectives effectively in a punctual manner. 
Furthermore, this systematic and integrated web environ-
ment let managers centrally process data much more easily 
than generic commercial software. 
1) Using AJAX (asynchronous Javascript and XML; e.g., 
Google), the pharmacists were provided a convenient input 
environment, the managers an efficient review environment, 
and the operators a comprehensive managerial environment 
[5].
2) Easy recover of previous dosage data
Since there are a number of similar generic products for a 
given drug, the usage/dosage would be identical for each of 
these cases. Therefore, without the need to reprocess identi-
cal information, previously processed data can be easily re-
trieved and appropriately reused to reduce processing time.
3) System request
The web based DUR data management system was designed 
to have a client-server architecture. This enables pharmacists 
to process and manage drug information on a PC running a 
generic web browser (i.e., client). All processed data is then 
stored in the DUR database (DB) of the DB server (Figure 1), 
meaning a web server processes the request for data. The 
web browser running on the PC of the client communicates 
with the web server under a HTTP 1.1 protocol, and in this 
regime, the requests for data and responses to this requests 
Figure 1. A client-server architecture in a drug utilization review (DUR) data manage system. DUR data manage system is constructed 
by connecting a database (DB) server to web server in which a manager program is built, for the purpose of facilitating 
multiple user's inputting and centralized managing DUR data. This client-server system enables multiple users input and 
manage data effectively rather than stand alone systems or files.270 http://dx.doi.org/10.4258/hir.2011.17.4.267 www.e-hir.org
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are exchanged in a manner similar to any web page access. 
In the construction of the DB used in this study, only one 
web server and one DB server was used instead of multiple 
web and DB servers since the system only used intermittent 
data processed at irregular intervals. Because of this small 
workload, there was no need to set-up multiple servers (e.g., 
load balancing, master-slave data replication), reducing the 
complexity of design and allowing its construction in a short 
period of time.
4) System development environment
The development tools used to construct a DUR data man-
agement system are listed in Table 1 [6,7].
5) Addition of fields
Since KFDA labels frequently contain unstructured natural 
language texts, pharmacists (i.e., inputters) are likely to ana-
lyze the information on the tags and then convert/process 
them into the structured data/database. Under this situation, 
the addition of an extra field may become necessary. The sys-
tem was made to be sufficiently flexible when adding these 
extra fields. The primary objective was to convert the data 
contained in the articles of the label and properly store them 
in the database by creating a DUR entry (Figure 2).
5. Usage Entry of KFDA Drugs
1) Drug products subjected to data entry
In general, the usage and dosage information of drugs ap-
proved by the KFDA, except for those excluded by the crite-
ria given below, were subjected to data entry. Since certain 
articles in the label may differ slightly even under identical 
ingredient codes, all data was processed based on the Drug 
Item Base Code.
  Exclusion criteria are combination drugs containing three 
or more active ingredients in one product, drug products for 
export, withdrawn drugs, radioactive drugs, X-ray contrast 
Figure 2. Diagram of the relationship among dosing information 
tables. A dosing information table is a kind of data-
base (DB) blueprint by which workers decide what in-
formation should be extracted from usage and dosage 
and then how it is processed. We made an effort to 
make the DB useful for dosing check-up substantially 
without distorting any meaning of original usage and 
dosage in a DB making process. Further continuous im-
provement in DB structure is needed. 
Table 1. System environments for the development of the drug utilization review (DUR) data managing system
Software Type Aim
Microsoft ASP.NET
a 3.5 Web application framework Develop.aspx web pages
Microsoft SQL Server 2008 RDBMS  Save/manage data
Prototype Javascript
Framework1.6
Javascript framework Realize asynchronous server communication using Ajax
Script.aculo.us 1.8.3 Javascript library 
(user interface)
Apply user interface fade in/out effect
Google Closure Library 4.0 Javascript library Create a template that generates a hyper text markup 
  language page as a function call using a closure template
Yahoo YUI compressor 
  (Javascript compression 
  utility developed by Yahoo)
Java command-line tool Reduce a file size by condensing Javascript code (253 KB → 
  129 KB, 50%)
ASP: active server pages, SQL: structured query language, RDBMS: relational database management system.
aASP.NET is a web application framework developed and marketed by Microsoft to allow programmers to build dynamic web sites, 
web applications, and web services.271 Vol.	17		•		No.	4		•		December	2011 www.e-hir.org
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media, diagnostic testing agents, dialysis irrigating solu-
tions, vaccines, blood-derived drugs, biological drugs, herbal 
medicines, and orphan drugs (biological drugs, herbal medi-
cines, blood-derived drugs, radioactive drugs, diagnostic 
testing agents, subcutaneous injections, and intramuscular 
injections).
2) Sources for dosing information
Ezdrug (http://ezdrug.kfda.go.kr), an official drug informa-
tion database from KFDA, was used to process dosage infor-
mation. Since it took approximately two minutes to display 
the information page (e.g., indication, usage/dosage and 
warning/precaution) of a particular drug product, the cu-
mulative delay in the process of information collection was 
significant. Therefore, relevant information was collected by 
analyzing the HTML source code of the Ezdrug webpage us-
ing Internet Explorer’s view source code menu. By entering 
CCBAA02L2 in the variable ‘CMD’ of http://ezdrug.kfda.
go.kr/kfda2 and the Drug Item Base Code in the variable 
‘itemseq’, a specific page in Ezdrug can be directly accessed. 
For example, the url ‘http://ezdrug.kfda.go.kr/kfda2?cmd=C
CBAA02L2&itemSeq=199300694’ gives direct access to the 
‘Albis Tab.’ drug information page. Making some optimiza-
tions, this access time can be reduced to approximately 30 
seconds.
3) Validation of processed information
The processed information was reviewed and its suitability 
was validated by two separate pharmacists from the hospital 
that participated in this study.
III. Results
1. Architecture of DUR Data Management System
This study finally built a database containing the dosing in-
formation for the 4,454 ethical injections and 12,450 ethical 
oral preparations currently being sold in the Korean market 
(July 2009). This accounts for 16,994 items in total, exclud-
ing the drugs omitted by the criteria mentioned above (e.g., 
radioactive drugs, X-ray contrast medium).
2. Modules for Dosing Information Management
Manager mode provides a module to check the propriety of 
prescribed dosages in specific cases. The criteria for this type 
of validation are established by building databases grouped 
by age and indication. Market approved information (dosage, 
dosing guidelines and clinical applications) was employed as 
the default standard of for dosages. The basic guidelines for 
manager mode and its key features are as follows:
1) In case of (a conditional unit)
In order to build a body of information for various types 
of dosage, a term ‘In case of’ was created as an information 
unit. The concept of this term is as follows; ‘in case of ~, the 
dosage schedule is ~’. As a detailed ‘In case of’ report tends 
to make dosing (numerical data) information more precise, 
a single dosing information should be correlated to a single 
specific ‘In case of’ report if possible, because this could 
reduce variations across operators caused by individual mis-
understandings. 
2) Age
While age standardization is important, it is difficult to 
define a standard age category in current drug market ap-
proved information. Several terms such as neonates, in-
fants, toddlers and children are mentioned, which have no 
numerically specification. Also, there are ambiguous terms 
regarding the aged population that tend to have little con-
sistency. To reduce the confusion from these ambiguous age 
terms, this study employed the age group guideline set by 
the KFDA in November 2008, which is based on the ICH 
guideline (Table 2).
3) Weight and body surface area (BSA)
Information on the patients’ weight and BSA is important 
in determining their dosing schedule. Thus, the system was 
developed to require the input of such information.
4) Dose
(1) Single dose or one day dose: The maintenance dose is en-
tered when there is information on both the initial dose and 
the maintenance dose. Only the initial dose is entered when 
there is no information concerning the maintenance dose. 
Also, the concept of an allowable maximum dose was imple-
mented, along with the usual minimum and maximum dose.
(2) Dose and dosing interval within a single course of therapy: 
The concept of ‘a single course of therapy’ was introduced 
to indicate the case that requires several repeated inputs of a 
Table 2. Age category
Term Age
Newborn infants 0 - under 28 days
Infants and toddlers 28 days - under 24 months 
Children 24 months - under 12 years
Adolescent 12 years - under 19 years
Geriatrics 65 years or older272 http://dx.doi.org/10.4258/hir.2011.17.4.267 www.e-hir.org
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particular medicine in a relatively short time. For instance, if 
a medication is given as an IV injection at doses of 1 mg/kg 
every 10 minutes until the symptoms resolve, the maximum 
interval and the minimum interval within a single course of 
treatment are both equivalent to 10 minutes. This field was 
newly defined in the present study because it could be an 
important concept that could check whether emergency in-
jections are appropriate in terms of dosing.
5) Duration of therapy, infusion time, and dosing intervals
(1) Duration of therapy: The ‘duration of therapy’ was used 
to indicate the relatively long treatment periods mentioned 
in the standard period the KFDA market approved infor-
mation recommends to achieve a therapeutic purpose. For 
example, if it suggests 4 weeks of treatment of Furing
Ⓡ tab 
(Phendimetrazine tartrate 35 mg), the duration of therapy is 
4 weeks.
(2) Infusion time: Infusion time denotes to the time taken 
for infusing a single dose of medicine. For instance, infusion 
time for an injected drug is 30 minutes if each dose is in-
fused for 30 minutes. This field can be used to check infusion 
speeds.
(3) Dosing intervals: The dosing interval denotes the time 
between two doses in cases where this time is significantly 
longer than the time of a single course of therapy described 
above. The dosing interval is 8 hours if 100 mg of a certain 
medication is treated every 8 hours.
6) Maximun/Minimun duration of treatment, drug holidays, 
and treatment cycles
A drug holiday is the period in which a patient stops taking a 
medication(s) for a period of time because of drug accumu-
lation or other adverse effects. Because it is a different con-
cept from the dosing interval mentioned above, new fields 
were created so operating staffs are able to input information 
on the minimum and maximum duration of treatment, drug 
holidays, and the number of treatment cycles.
7) Dosing adjustment in renal or liver dysfunction
Manager mode also allows medical personnel to check if 
dosing adjustment is required due to renal or hepatic dys-
function.
8) Other additional fields
It may be necessary to add new field to input strange DUR 
information into database. In that case, Manager mode can 
be updated to add new field into database with slight editing 
in source-code and database.
9) Others
(1) KFDA: The KFDA information can be acquired by either 
connecting to a link on the web or by directly referring to 
texts in the database.
(2) References: There are tools that allow users to look up 
further dosing information in the AHFS Drug Information, 
Pharmaceuticals and Medical Devices Agency and Martindale.
(3) Notes: There was a field for notes where operators left 
their opinions, abnormal issues, etc., making references for 
reviewers.
3. Usage Outline of Web-based Data Management System
1) Log in
Log in to the DUR data managing web (http://www.drugin-
fo.co.kr/dur/admin) to access the system.
2) Product search
(1) To search any product at the manager home after con-
necting, select a searching option. The default is the national 
product code (Figure 3).
Figure 3. Drug utilization review (DUR) manager home 1. DUR 
manager home supports diverse options search for 
DUR data. It also enables operators to manage “my 
work list” and “whole workers‘ work list”.273 Vol.	17		•		No.	4		•		December	2011 www.e-hir.org
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(2) The list of search results appears as shown in Figure 4. 
The total number of search results is presented at the top 
of the page. The maximum number of products that can be 
presented on a single page is 10. By clicking a product name, 
operators are transferred to a page where they can add and 
manage data.
3) Data input and management by national product codes
(1) Data Input: Choosing the link [Data Input] in the left 
menu bar opens a screen for a data entry mode (Figure 5). 
Click the [Save] at the top to save data after finishing data 
input.
(2) Managing data: The new system provides tools for opera-
tors to review, amend, and remove data from the database.
(3) Data import: The tool [Data Import] is a function that 
allows operators to copy information from previous data to 
the current entry form without entering any data [Data in-
put]. This is useful to enhance work speed when the dosing 
information of one product is identical to a data set already 
entered. Clicking the [Data Import] button after entering the 
national product code for the previous data set that the op-
erators want to copy will load the copied data to the current 
entry form.
(4) Data browsing: Data and data entry times can be checked 
and searched through the [Work Breakdown] function in 
several ways. Clicking the link [All Work Breakdown] in 
the left menu presents the total number recent operations 
and lists them in chronological order. To perform a detailed 
browse in a different way, operators can choose various 
searching options such as [worker] to search for progress 
made by that specific worker.
4. Modules for Export of Dosing Information
1) Dosing information in the established database can be ex-
ported into an Excel spreadsheet for printing. Figure 6 pres-
ents an example of the exported data showing drug profiles, 
‘In case of’ information, and original texts.
2) Checking dosages against the KFDA’s approval information
Figure 4. Drug utilization review manager home 2. It shows the 
searched sum-up information on work-list data and 
searched results. And it also displays a current input-
ting work status on DUR data. Product's name and 
other list information are written in Korean becasue 
our Database was targetted to drugs  saled in Kore.
Figure 5. Drug utilization review manager home 3. This picture 
shows the “input mode on a case basis” for entering 
detailed information on a specific drug. It supports 
a quick move to diverse input categories. Separating 
numerical values and unit values in the beginning of 
data input made workers possible to enter the same 
unit values consistently and check up the dosing data 
instantly.
Figure 6. An Excel spreadsheet of dosing information from the 
established database. Inputted data can be printed in 
an Excel sheet form. And it also can be converted in 
any forms (easy to understand and handy to manage) 
by analyzing an enormous amount of inputted infor-
mation via Visual Basic for Application program de-
veloped to process a data. DUR contents are written in 
Korean, because we analyzed contents based on Korean 
Food and Drug Administration's drug label infomation.274 http://dx.doi.org/10.4258/hir.2011.17.4.267 www.e-hir.org
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One important purpose of this project was to set up a stan-
dard for a dosage check and, moreover, to utilize this estab-
lished standard in the DUR program. To give a trial perfor-
mance in a simple manner, a new dosage checking program 
was developed based on the established dosing information. 
In other words, a Visual Basic for Application (VBA) pro-
gram that checks the propriety of the dosages was loaded 
onto a converter program. As shown in Figure 7, users can 
open a window for a dose check easily by clicking the [Quick 
Dosage Check] button in an output sheet. When a window is 
popped up, users can retrieve a drug profile by entering the 
national product code of the drug they would like to check 
(Figure 7). Then, users can input a dose (that users want to 
check) in a pertinent option(s). Clicking the [Check] button 
shows the results in a separate textbox. 
IV. Discussion
As prescriptions reimbursed by public funds are rapidly in-
creasing in the Korea National Health Insurance, constant 
efforts to utilize information technology have been made as 
an attempt to improve documentation accuracy as well as to 
save time. However, computerized DUR systems have never 
been developed at a nationally level, and these systems were 
always developed by local organizations. This is thought to 
come from the following potential factors. First of all, every 
hospital has its own operating system. As a result, standard 
systems that can be applied to all hospitals are hard to de-
velop. Also, professionals in the field tend to underestimate 
the effectiveness of digitized DUR systems due to the lack of 
information provided to them [8].
  Therefore, this study built a dosage database for locally 
marketed ethical pharmaceuticals based on KFDA approved 
information on indications and predefined age category dosages.
  The system was developed in three steps. The first step 
was to build a web-based manager mode in which multiple 
operators were able to connect at the same time to build 
a dosing database. The manager mode program had to be 
easy for users to learn and capable of doing the users needs 
while also being secured and automatically backed up. The 
next step was to establish a real dosing database. This stage 
was challenging and often required changes in the pre-estab-
lished manager mode program. The last step was to develop 
a tool that could review the established data and to develop 
a method to submit the database as an outcome of the study. 
Lessons learned from this study are summarized in the fol-
lowing:
1. Redundancy
Redundancy denotes cases where there are more than two 
ways to express the dosage. Examples may include similar 
and identical expressions to those shown in Figure 8. In such 
cases, this study tried to stick to the official market approved 
expression as much as possible. In the future, it is recom-
mended that an independent and consistent converting 
Figure 7. An Visual Basic for Application (VBA) example of Quick 
Dosage Check in an exported drug utilization review 
(DUR) data. VBA code can enhance utilization of DUR 
data exported in the excel sheet form. It can process 
data, and also check dosage data in an excel environ-
ment. VBA code makes specific data possible to be con-
verted into a variety of media (HTML, MDB, TXT, JAVA-
SCRIPT, etc.) and to be modified into a lot of forms. 
VBA code helps managers to makes the better use of 
DUR data.
Figure 8. Examples of redundancy. One can find many occasions 
in which the same or similar expressions (in the label) 
slightly differ in numerical values or unit values when 
inputting dosage information on a case basis. This 
situation is defined as redundancy of drug utilization 
review (DUR) information. In any circumstances, the 
same results should be come out by processing regard-
less of the kind of values. This manager program has a 
unit conversion function by which unit information is 
separated and inputted independently.275 Vol.	17		•		No.	4		•		December	2011 www.e-hir.org
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module should be built in the DUR program.
2. Increasing or Decreasing Dosage
While a field that shows dosage dynamics (the trend of dos-
age change over time) is important for DUR services, the 
present study failed to reflect it due to limitations in time. 
  Beyond the simple implications of increase and/or decrease, 
the information included in the new field should contain 
several different aspects of dosage change such as time, 
quantity, and frequency. Hence, the technique in demand 
may be to first produce database templates for every field in 
the basic information database and then assign templates to 
each newly created dynamic dosage category when new cat-
egories are needed.
3. Issues in the New Concept of ‘In case of’
Applying the new concept of ‘In case of’ to dosing informa-
tion was challenging. To keep decision making in this line of 
thinking objective, loading a standardized guideline onto the 
manager mode program seems necessary in future research. 
4. Implications for the Future Dosing Information Systems
Digital codes from Systematized Nomenclature of Medicine 
(SNOMED) or ATC codes may benefit the future system in 
terms of efficiency in comparison with the text information 
employed in this study. To reduce the confusion caused by 
the frequent adding or deleting of dosage fields that often de-
layed the working process, it is recommendable to consider 
an independent MARKUP language that digitalizes dosing 
information more easily as shown below:
  250 mg, once per day, maximum 500 mg → day length=1 
times=1 norm_dose=250 dose unit=mg max dose=500 dose 
unit=mg
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